Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study of CAP-1002 in Ambulatory and Non-Ambulatory Patients With Duchenne Muscular Dystrophy (HOPE-3) (HOPE-3)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05126758
Recruitment Status : Recruiting
First Posted : November 19, 2021
Last Update Posted : May 20, 2022
Sponsor:
Information provided by (Responsible Party):
Capricor Inc.

Brief Summary:
HOPE-3 is a multi-center, randomized, double-blind, placebo-controlled clinical trial evaluating the safety and efficacy of a cell therapy called CAP-1002 in study participants with Duchenne muscular dystrophy (DMD) and impaired skeletal muscle function. Non-ambulatory and ambulatory boys and young men who meet eligibility criteria will be randomly assigned to receive either CAP-1002 or placebo every 3 months for a total of 4 doses during a 12-month period. All participants will be eligible to receive CAP-1002 for an additional 12 months as part of an open label extended safety assessment period.

Condition or disease Intervention/treatment Phase
Muscular Dystrophies Muscular Dystrophy, Duchenne Muscular Disorders, Atrophic Muscular Diseases Neuromuscular Diseases Genetic Diseases, X-Linked Genetic Diseases, Inborn Nervous System Diseases Biological: CAP-1002 Drug: Placebo Phase 3

Detailed Description:

Up to 68 eligible study participants will be randomized to either CAP-1002 or placebo in a 1:1 ratio. The trial will include visits at Screening, Baseline/Day 1, Week 4, and Months 3, 6, 9, and 12 with IV infusions of CAP-1002 or placebo on Day 1 and Months 3, 6, and 9.

The primary analysis of efficacy and safety will be performed at Month 12 following 4 administrations of CAP-1002 or placebo.

The primary efficacy endpoint is the mean change from baseline in upper limb function as assessed by the full Performance of the Upper Limb test, version 2.0 [PUL 2.0] at the 12-month time point. Secondary endpoints evaluated at the 12-month time point include assessment of changes in cardiac muscle function and structure by cardiac magnetic resonance imaging [cMRI], changes in hand-to-mouth function [eat 10-bites assessed by the Duchenne Video Assessment (DVA)], and quality of life assessments.

Safety evaluations will include adverse events, concomitant medications, physical exam, vital signs, 12-lead ECG, and clinical laboratory testing.

Following the initial 4 infusions, all subjects will be eligible to participate in a 12-month open label extended safety assessment period and receive up to 4 additional IV infusions of CAP-1002 once every 3 months. An analysis of extended safety will be conducted after all subjects have completed the Month 24 visit.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 68 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Efficacy and Safety of Human Allogeneic Cardiosphere-Derived Cells for the Treatment of Duchenne Muscular Dystrophy
Estimated Study Start Date : May 2022
Estimated Primary Completion Date : December 2024
Estimated Study Completion Date : December 2025


Arm Intervention/treatment
Active Comparator: CAP-1002
Patients will receive 150 million cardiosphere-derived cells (CDCs) via intravenous infusion every 3 months for a total of 4 doses.
Biological: CAP-1002
CAP-1002 is a cell therapy consisting of human allogeneic cardiosphere-derived cells (CDCs). CDCs are known to secrete numerous bioactive elements (growth factors, exosomes) which impact the therapeutic benefits of the cell-based therapy. The mechanism of action is the composite ability to be immunomodulatory, anti-fibrotic and regenerative.
Other Name: Cardiosphere-Derived Cells (CDCs)

Placebo Comparator: Placebo
Patients will receive a placebo solution via intravenous infusion every 3 months for a total of 4 doses.
Drug: Placebo
Placebo




Primary Outcome Measures :
  1. Change in full upper limb function [ Time Frame: At Month 12 ]
    Mean change from baseline in full Performance of the Upper Limb test, version 2 (PUL 2.0). items are scored on a three-point scale: 0=unable to perform the item, 1=impaired or performs with compensation, 2=performs task without compensation


Secondary Outcome Measures :
  1. Change in cardiac muscle function and structure by assessment of ejection fraction [ Time Frame: At Month 12 ]
    Mean change from baseline in ejection fraction as assessed by Cardiac Magnetic Resonance (cMRI)

  2. Change in cardiac muscle function and structure by assessment of left ventricular end-systolic volume [ Time Frame: At Month 12 ]
    Mean change from baseline in left ventricular end-systolic volume as assessed by Cardiac Magnetic Resonance (cMRI)

  3. Change in cardiac muscle function and structure by assessment of left ventricular end-diastolic volume [ Time Frame: At Month 12 ]
    Mean change from baseline in left ventricular end-diastolic volume as assessed by Cardiac Magnetic Resonance (cMRI)

  4. Change in elbow and distal level upper limb function [ Time Frame: At Month 12 ]
    Mean change from baseline in mid [elbow] plus distal level upper limb function in Performance of the Upper Limb test, version 2 (PUL 2.0); items are scored on a three-point scale: 0=unable to perform the item, 1=impaired or performs with compensation, 2=performs task without compensation

  5. Change in hand-to-mouth function in the context of functional eating [ Time Frame: At Month 12 ]
    Mean change from baseline in the functional ability of eating 10 bites evaluated by Duchenne Video Assessment (DVA) using a video record of patient performing the task at home. Physical therapists score the patient's quality of movement in the video using scorecards with pre-specified compensatory movement criteria.

  6. Change in hand-to-mouth function [ Time Frame: At Month 12 ]
    Mean change from baseline in item 7 [hand-to-mouth] in Performance of the Upper Limb test, version 2 (PUL 2.0); items are scored on a three-point scale: 0=unable to perform the item, 1=impaired or performs with compensation, 2=performs task without compensation

  7. Number of patients with total loss of hand-to-mouth function [ Time Frame: At Month 12 ]
    Proportion of patients with total loss of hand-to-mouth function as assessed by item 7 [hand-to-mouth] in Performance of the Upper Limb test, version 2 (PUL 2.0)

  8. Changes in patient-reported upper limb function [ Time Frame: At Month 12 ]
    Mean change from baseline in Duchenne Muscular Dystrophy Upper Limb Patient-Reported Outcome Measures (DMD UL PROM) questionnaire. Patient or caretaker evaluates the perceived difficulty in performing activities of daily living on a 3-level scale: 0=impossible without help, 1=can do task with difficulty, 2= can do task easily.

  9. Changes in cardiac inflammation biomarker, creatine kinase MB isoenzyme [CK-MB] [ Time Frame: At months 1, 3, 6, 9, 12 ]
    Mean change from baseline in CK-MB blood levels - MB fraction (% of total CK).



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   10 Years and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Male subjects at least 10 years of age at time of consent who are willing and able to provide informed consent to participate in the trial and diagnosed with DMD as confirmed by the Investigator
  2. Genetically confirmed DMD
  3. Performance of the Upper Limb test (PUL) entry item scores 2-6 and total PUL score less than or equal to 40
  4. Reduced ability to walk/run (if ambulatory): 10-meter walk/run velocity < 1 meter/second and total PUL score of less than or equal to 40
  5. Loss of independent ambulation between 10th and 18th year birthday
  6. Treatment with systemic glucocorticoids for at least 12 months and at a stable dose at least 6 months prior to study participation, except for weight-based or toxicity-related adjustments
  7. Current and up-to-date immunizations
  8. Adequate venous access for parenteral IP infusions and routine blood collection
  9. Assessed by the Investigator as willing and able to comply with the requirements of the trial

Exclusion Criteria:

  1. Left ventricular ejection fraction (LVEF) < 35%
  2. Elbow-flexion contractures > 30° in both extremities
  3. Body mass index (BMI) > 45
  4. Percent predicted forced vital capacity (FVC%) < 35%
  5. Inability to perform consistent PUL 2.0 measurement within ± 2 points without shoulder domain or within ± 3 points with shoulder domain during paired testing at screening
  6. Risk of near-term respiratory decompensation in the judgment of the Investigator, or the need for initiation of day and night non-invasive ventilator support as defined by serum bicarbonate ≥ 29 mmol/L at screening
  7. History of non DMD-related chronic respiratory disease requiring ongoing or intermittent treatment, including, but not limited to, asthma, bronchitis, and tuberculosis
  8. Acute respiratory illness within 30 days prior to screening and during screening
  9. Initiation of nocturnal non-invasive ventilation within 30 days prior to screening
  10. Planned or anticipated thoracic or spinal surgery within the 6 months following randomization
  11. Planned or anticipated lower extremity surgery within the 6 months following randomization, if ambulatory
  12. Known hypersensitivity to dimethyl sulfoxide (DMSO) or bovine products
  13. Initiation of treatment with metformin or insulin within 3 months prior to randomization
  14. Initiation of treatment with an FDA-approved exon skipping therapy for the treatment of DMD within 24 months prior to randomization or dose adjustments to the therapy within 12 months prior to randomization with the exception of weight-based dose adjustments
  15. Treatment with human growth hormone within 3 months prior to randomization, unless on a stable dose allowing for weight-based dose adjustments (as determined by the site Investigator) for at least 24 months prior to randomization
  16. Treatment with a cell therapy product within 12 months prior to randomization
  17. Treatment with an investigational product within 6 months prior to randomization
  18. History, or current use, of drugs or alcohol that could impair the ability to comply with participation in the trial
  19. Inability to comply with the investigational plan and follow-up visit schedule for any reason, in the judgment of the investigator

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05126758


Contacts
Layout table for location contacts
Contact: Daniel Paulson, MD 805.449.3824 dpaulson@capricor.com
Contact: Peter Stiegler, PhD 310.358.3046 pstiegler@capricor.com

Locations
Layout table for location information
United States, Arkansas
Arkansas Children's Hospital Recruiting
Little Rock, Arkansas, United States, 72202
Contact: Ankita Patel    501-364-1035    patelA1@archildrens.org   
Principal Investigator: Aravindhan Veerapandiyan, MD         
United States, California
University of California, Davis Not yet recruiting
Sacramento, California, United States, 95817
Contact: Megan Jones    916-734-5057    megjones@ucdavis.edu   
Principal Investigator: Craig McDonald, MD         
United States, Georgia
Rare Disease Research, LLC Recruiting
Atlanta, Georgia, United States, 30329
Contact: Brenda Almaras    678-883-6897    brenda.almaras@rarediseaseresearch.com   
Principal Investigator: Han Phan, MD         
Sponsors and Collaborators
Capricor Inc.
Investigators
Layout table for investigator information
Principal Investigator: Craig McDonald, MD University of California, Davis
Layout table for additonal information
Responsible Party: Capricor Inc.
ClinicalTrials.gov Identifier: NCT05126758    
Other Study ID Numbers: CAP-1002-DMD-04
First Posted: November 19, 2021    Key Record Dates
Last Update Posted: May 20, 2022
Last Verified: May 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Capricor Inc.:
Duchenne Muscular Dystrophy
Cell Therapy
Performance of the Upper Limb
Ambulatory
Non-Ambulatory
Additional relevant MeSH terms:
Layout table for MeSH terms
Muscular Dystrophies
Muscular Dystrophy, Duchenne
Muscular Diseases
Muscular Disorders, Atrophic
Nervous System Diseases
Neuromuscular Diseases
Genetic Diseases, Inborn
Genetic Diseases, X-Linked
Musculoskeletal Diseases